The Effect of Interleukin-4 and Amphiregulin on the Proliferation of Human Airway Smooth Muscle Cells and Cytokine Release by Shim, Jung Yeon et al.
INTRODUCTION
Asthma, a chronic airway inflammatory disease, is charac-
terized by reversible airway obstruction, airway inflamma-
tion and airway hyperreactivity. Repeated airway inflamma-
tion can lead to irreversible structural change and airflow
obstruction, namely airway remodeling. Airway smooth
muscle (ASM) cell hyperplasia and hypertrophy are key fac-
tors in airway remodeling (1). Airway smooth muscle cells
are the major effector cells that regulate bronchomotor tone
in asthma. However, new evidence suggests that ASM cells
are also an important source of pro-inflammatory cytokines,
chemokines, growth factors, and extracellular matrix (ECM)
components (2).
Interleukin (IL)-4 and IL-13 are T helper (Th) 2 lympho-
cyte-derived cytokines that induce T cell differentiation to a
Th2 phenotype as well as isotype switching of B cells to IgE
producing cells. Even though experimental evidence has
firmly established a key role for IL-4 and IL-13 in acute aller-
gic inflammation (3), their activity in airway remodeling
has not been fully elucidated. IL-4 and IL-13 act through a
common subunit of their receptor complexes, the IL-4 recep-
tor αsubunit (IL-4Rα ) in ASM cells, and regulate allergic
inflammation and tissue remodeling in the airways (4). IL-
4Rα -deficient mice fail to develop goblet-cell metaplasia and
airway hyperreactivity (5). However, many studies have shown
greater activity of IL-13 compared to IL-4 in allergic inflam-
mation including goblet-cell metaplasia, mucus overproduc-
tion, airway hyperreactivity, ASM cell migration, and airway
remodeling (3, 6, 7, 8). Furthermore, it has been suggested
that they have different activities in their effector properties;
IL-4 plays a more prominent role in the initiation phase of
Th2 inflammation, whereas IL-13 is more prominent in the
effector phase of Th2 inflammation (1). IL-4 has been shown
to have either proliferative or anti-proliferative properties
depending on the cell type (9-14). However, there is limit-
ed information on the effect of IL-4 on airway smooth mus-
cle cell proliferation (12). 
The vascular endothelial growth factor (VEGF) contributes
to the airway remodeling in asthma by increasing angiogene-
sis and vascular permeability. Patients with asthma have been
shown to have increased levels of VEGF in bronchoalveolar
lavage fluid as well as VEGF receptor positive vessels in biop-
sy samples (15). The effect of IL-4 on the regulation of VEGF
has not been completely characterized. In smooth muscle cells,
IL-4 and IL-13 have been shown to increase VEGF expres-
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The Effect of Interleukin-4 and Amphiregulin on the Proliferation of
Human Airway Smooth Muscle Cells and Cytokine Release 
Airway smooth muscle (ASM) hyperplasia and angiogenesis are important features
associated with airway remodeling. We investigated the effect of IL-4 and amphireg-
ulin, an epidermal growth factor family member, on the proliferation of human ASM
cells and on the release of vascular endothelial growth factor (VEGF) and mono-
cyte chemotactic protein (MCP)-1 from human ASM cells. Human ASM cells were
growth-arrested for 48 hr and incubated with platelet-derived growth factor (PDGF)-
BB, interleukin (IL)-4, amphiregulin, and VEGF to evaluate cell proliferation. The
cells were treated with PDGF, IL-4 and amphiregulin to evaluate the release of
VEGF, MCP-1. IL-4 suppressed unstimulated and PDGF-stimulated ASM cell pro-
liferation. Amphiregulin stimulated ASM cell proliferation in a dose-dependent man-
ner. VEGF did not have any influence on ASM cell proliferation. IL-4 stimulated
VEGF secretion by the ASM cells in a dose-dependent manner and showed added
stimulatory effects when co-incubated with PDGF. Amphiregulin did not promote
VEGF secretion. IL-4 and amphiregulin showed no stimulatory effects on MCP-1
secretion. The results of this study showed that IL-4 had bifunctional effects on air-
way remodeling, one was the suppression of the proliferation of the ASM cells and
the other was the promotion of VEGF release by the ASM cells, and amphiregulin
can promote human ASM cell proliferation. 
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Accepted : 18 January 2008sion (16, 17). On the other hand, in patients with rheuma-
toid arthritis, IL-4 inhibits VEGF production in synovial
fibroblasts (18). Furthermore, to date, the effects of VEGF
on cellular proliferation remain unclear.
In this study, we investigated the impact of IL-4, VEGF,
and amphiregulin on the proliferation of human ASM cells.
Amphiregulin is a polypeptide growth factor that belongs
to the epidermal growth factor (EGF) family. Amphiregulin,
like other EGF family members, plays an important role in
cell processes. These include cell proliferation, survival, dif-
ferentiation, and migration. However, it has not been demon-
strated whether amphiregulin can promote human ASM cell
proliferation. In addition, we evaluated whether IL-4 and
amphiregulin induced the release of VEGF, MCP-1 and MIP-
1αfrom ASM cells. 
MATERIALS AND METHODS
Human ASM cell culture
Primary human ASM cells and cell growth supplement
were purchased from Clonetics (San Diego, CA, U.S.A.).
Penicillin, streptomycin, fetal bovine serum (FBS) and 10%
Dulbecco’s modified Eagle’s medium (DMEM), DMEM/F-
12 medium were obtained from Gibco BRL. Bovine serum
albumin (BSA) and insulin-transferrin-selenium (ITS) were
obtained from Sigma. IL-4, amphiregulin, platelet-derived
growth factor (PDGF)-BB, VEGF, monoclonal anti-human
VEGF antibody, and monoclonal anti-human VEGF R2 anti-
body were purchased from R&D (R&D systems, Minneapo-
lis, MN, U.S.A.). 
Human ASM cells were placed in 75 cm2 culture flask
with 10% FBS/DMEM containing 100 IU/mL penicillin,
100 μ g/mL streptomycin, and 2 mM L-glutamine and incu-
bated in a humidified incubator at 37℃, 5% CO2. When
the cells became confluent, they were passaged with the use
of 0.025% trypsin in 0.01% EDTA. Cells at passages 3 to 6
were used in all experiments.
Analysis of human ASM cell proliferation
Human ASM cells were seeded at a density of 1×104cells/
cm2 in 96-well culture plates. When cells reached 70% con-
fluence, growth was arrested in serum-free DMEM/F-12
medium containing 0.1% BSA for 48 hr. The cells were then
incubated with 20 ng/mL of PDGF-BB, 10, 50, and 100
ng/mL of IL-4, 10, 30, and 50 ng/mL of VEGF and 10, 50,
and 100 ng/mL of amphiregulin for 48 hr. Cells were also
treated with 100 ng/mL of monoclonal anti-human VEGF
antibody and/or 100 ng/mL monoclonal anti-human VEGF
R2 antibody in the presence of PDGF to evaluate the effect
of VEGF on the cell proliferation. 
Cell proliferation was measured using a bromodeoxyuri-
dine (BrdU) cell proliferation ELISA kit (Roche Applied
Science, Mannheim, Germany). Briefly, cells were cultured
in 96-well plates under the conditions described above and
incubated with 10 μ M BrdU for 24 hr. BrdU incorporation
into DNA was detected using a commercial kit.
Cytokine assay
To evaluate the effect of cytokines on the production of
VEGF, MCP-1 and MIP-1αfrom human ASM cells, the cells
were cultured to confluence in 10% FCS/DMEM in humidi-
fied 5% CO2air at 37℃in 24-well culture plates and growth-
arrested in serum-free DMEM/F-12 medium for 48 hr. Cells
were stimulated with 20 ng/mL of PDGF-BB, 10, 50, and
100 ng/mL of IL-4 and 50, 100, and 150 ng/mL of amphireg-
ulin. After 24-hr incubation, the cell culture supernatant
was harvested and stored at -80℃ until the ELISA for cyto-
kines was performed. 
Measurement of VEGF, MCP-1, MIP-1αby ELISA
ELISA was used to analyze VEGF, MCP-1 and MIP-1αin
cell culture supernatants according to the manufacture’s man-
uals (R&D systems). The minimum detectable doses of cyto-
kines were less than 5 pg/mL for VEGF and MCP-1 and less
than 10 pg/mL for MIP-1α .
Statistics
Each experiment was repeated on multiple occasions, with
triplicate dishes. Data were evaluated by one-way ANOVA
followed by Bonferroni’s multiple comparison tests.
RESULTS
Effect of IL-4 on the proliferation of human ASM cells
Fig. 1 shows the proliferation of human ASM cells treated
with 20 ng/mL of PDGF and the indicated concentrations
of IL-4. IL-4 significantly suppressed the proliferation of
ASM cells at 10, 50, and 100 ng/mL compared to the untreat-
ed cells (p<0.001). To determine the effect of IL-4 on PDGF-
induced proliferation, the cells were treated with IL-4 in the
presence of PDGF. IL-4 also significantly inhibited the PDGF-
induced proliferation of ASM cells at 10 and 100 ng/mL (p<
0.001) (Fig. 1).  
Effect of amphiregulin on the proliferation of human ASM
cells 
To evaluate the effect of amphiregulin on the proliferation
of ASM cells, different concentrations of amphiregulin were
added to the cultured ASM cells. Amphiregulin induced
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We also evaluated the effect of amphiregulin on the prolif-
eration of ASM cells in combination with PDGF. However,
amphiregulin did not demonstrate synergistic effects on cell
proliferation compared to the proliferation of cells stimulat-
ed with PDGF only (Fig. 2). 
Effect of VEGF on the proliferation of human ASM cells
Fig. 3 shows the effect of VEGF on the proliferation of
human ASM cells. Cells were incubated with 10, 30, and 50
ng/mL of VEGF for 48 hr. However, VEGF did not show
any effect on the proliferation of ASM cells at all concentra-
tions, whereas PDGF increased the proliferation of ASM cells.
When ASM cells were incubated with VEGF in combina-
tion with PDGF, the proliferation was not augmented com-
pared to that of cells treated with PDGF only. 
When ASM cells were incubated with PDGF, not only
cell proliferation but also VEGF secretion was elevated. We
investigated whether ASM cell proliferation could be regu-
lated by anti-VEGF antibody or anti-VEGF R2 antibody.
ASM cells were stimulated with PDGF and treated with
100 ng/mL of anti-human VEGF antibody and/or 100 ng/
mL of anti-human VEGF R2 antibody in presence of PDGF.
However, neither anti-human VEGF antibody nor anti-human
VEGF R2 antibody influenced ASM cell proliferation (Fig. 3). 
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Fig. 1. Effect of IL-4 on the proliferation of human ASM cells. (A) When cells were treated with IL-4 (10, 50, and 100 ng/mL), cell proliferation
was significantly suppressed at all concentrations compared to control cells. *p<0.001 vs. Control and PDGF. (B) When cells were treat-
ed with IL-4 (10, 100 ng/mL) in presence of PDGF, IL-4 inhibited PDGF-enhanced cell proliferation. 
� p<0.001 vs. PDGF.
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Fig. 2. Effect of amphiregulin on the proliferation of human ASM cells. (A) Amphiregulin induced cell proliferation in a dose-dependent
manner. Amphiregulin significantly enhanced cell proliferation at 50 and 100 ng/mL. *p<0.01 vs. Control. (B) Amphiregulin was added in
combination with PDGF to compare the proliferation of cells treated with PDGF only. Proliferation of cells treated with amphiregulin and
PDGF did not show an add-on effect compared to the proliferation of cells treated with PDGF only. *p<0.01 vs. Control.  
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Fig. 3. (A) Effect of VEGF on the proliferation of human ASM cells. VEGF did not enhance cell proliferation at 10, 30, and 50 ng/mL. (B)
Effect of anti-VEGF antibody and anti-VEGF R2 antibody on the PDGF-enhanced cell proliferation. Both 100 ng/mL of anti-VEGF antibody
and/or 100 ng/mL of anti-VEGF R2 antibody did not influence PDGF-augmented cell proliferation. VEGF did not augment PDGF-enhanced
cell proliferation when cells were treated with 10 ng/mL of VEGF in combination with PDGF. *p<0.01 vs. Control.  
B
0.0 0.1 0.2
P+Vab+VRab
P+Vab
PDGF
Control
O.D (450 nm) A
0.0 0.1 0.2 0.3
VEGF50
VEGF30
VEGF10
PDGF
Control
O.D (450 nm)
*
*
*
P+VRab *
*
P+VEGF10 *Effect of IL-4 and amphiregulin on cytokine release of
human ASM cells
Fig. 4 shows the release of VEGF by human ASM cells
treated with the indicated concentration of IL-4, amphireg-
ulin and PDGF for 24 hr. The concentration of VEGF releas-
ed from control ASM cell culture was approximately 1,046±
81.99 pg/105 cells. IL-4 increased the production of VEGF
by human ASM cells in a concentration-dependent manner
(p<0.001). PDGF (20 ng/mL) also significantly increased
VEGF secretion from the human ASM cells (p<0.001). We
evaluated the release of VEGF by ASM cells treated with
the indicated concentrations of IL-4 in presence of PDGF.
The release of VEGF by cells treated with IL-4 and PDGF
was significantly higher than that of the cells incubated with
PDGF only (p<0.01). Amphiregulin treatment had little
effect on VEGF release from the human ASM cells at all con-
centrations (50, 100, and 150 ng/mL) (Fig. 4). 
Fig. 5 shows the effect of IL-4, amphiregulin and PDGF
on the release of MCP-1. PDGF increased the release of MCP-
1 from the ASM cells, whereas IL-4 and amphiregulin had
little stimulatory effect on MCP-1 secretion at 50 and 100
ng/mL concentrations (Fig. 5). MIP-1αwas not detected in
the cultured cell supernatants (data not shown). 
DISCUSSION
In this study, IL-4 inhibited the proliferation of stimulat-
ed and unstimulated human ASM cells. The lowest inhibito-
ry concentration of IL-4 was 10 ng/mL, and the inhibition
was not dose dependent. Both IL-4 and IL-13 have been
shown to play a key role in regulating allergic inflammation
and Th2-induced tissue remodeling (19, 20). However, the
actual role of IL-4 on airway remodeling has not been fully
elucidated. Even though IL-4 and IL-13 have in common
the IL-4 receptor, IL-4Rα , originally, IL-13 was presumed
to have the same effector function as IL-4. However, new evi-
dence suggests that they have different roles in allergic inflam-
mation and airway remodeling. IL-4-mediated remodeling
responses have been reported to be less efficient than IL-13
(1, 3, 7). In a study using transgenic Balb/c mice, the mice
with the IL-4 transgene do not show airway wall fibrosis or
bronchial hyperreactivity, whereas IL-13 promotes subep-
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Fig. 4. Effect of IL-4 and amphiregulin on VEGF release by human
ASM cells. (A) IL-4 (10 and 100 ng/mL) enhanced VEGF release
in a dose-dependent manner. PDGF (20 ng/mL) also significantly
increased VEGF release. *p<0.001 vs. Control, IL4-100 and PDGF.
(B) IL-4 (10 and 100 ng/mL) increased PDGF-enhanced VEGF
secretion. *p<0.01 vs. Control and PDGF. 
� p<0.01 vs. Control. (C)
Amphiregulin (50, 100, and 150 ng/mL) did not augment VEGF
secretion at all concentrations. *p<0.001 vs. Control, AR50, AR100
and AR150.
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Fig. 5. Effect of IL-4 and amphiregulin on MCP-1 release by human ASM cells. PDGF (20 ng/mL) increased MCP-1 release. However, neither
IL-4 (50 and 100 ng/mL) nor amphiregulin (50 and 100 ng/mL) augmented MCP-1 release by human ASM cells. *p<0.05 vs. Control. 
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*ithelial fibrosis, goblet-cell metaplasia and smooth-muscle
cell proliferation (7, 21). However, IL-4-induced fibrosis
appears to be a strain-specific response, since recent findings
showed that fibrosis was found in transgenic IL-4 C57BL/6
mice in contrast to Balb/c mice (22). IL-13 has also been
shown to augment human ASM migration toward PDGF,
while IL-4 does not (8, 23). IL-13, but not IL-4, enhances
Src-kinase phosphorylation and increases human ASM cell
migration. Src is a key member of the mitogenic signaling
cascade in many cell types (23). PDGF and EGF induce rapid
activation of Src and promote cell proliferation. It is possible
that failure of Src-kinase phosphorylation of IL-4 contributes
to the inhibition of ASM cell proliferation.
IL-4 has different regulatory functions in cell proliferation
depending on the cell type. IL-4 suppresses the proliferation
of human tumor cell lines, astrocytes, human umbilical vein
endothelial cells, vascular smooth muscle cells, pre-adipocyte
cells, and airway smooth muscle cells, while it promotes the
proliferation of fibroblasts and endothelial cells (10, 12, 24-
28). IL-4Rαas well as IL-13Rα I and IL-13Rα II have all been
reported to be a constitutively expressed in human ASM cells
(4, 29). However, there is limited data on the signaling path-
way of IL-4 after it binds to its receptor. In one study, on cul-
tured human ASM cells, IL-4 and IL-13 activated IL-4Rα
and induced phosphorylation of its signal tranducer and acti-
vation of transcription-6 (STAT6), p42/p44 ERK and p38
mitogen-activated protein (MAP) kinase in cultured human
ASM cells (29). However, since ERK and p38 MAP kinase
are known to be important intracellular pathways for cell
proliferation (30), it is unlikely that IL-4 suppresses ASM
cell proliferation through them. It has been suggested that
IL-4 decreases ASM cell proliferation by a decrease in cyclin
D1 protein expression rather than a c-AMP dependent mech-
anism (12) or through STAT6 activation (28). However, IL-
4 also enhances PDGF-induced proliferation in fibroblasts
via the STAT6 pathway (31). Therefore, IL-4 appears to play
a different role based on the cell type via mainly STAT6. 
Contrary to our results, it has been suggested that IL-4 and
IL-13 induce ASM cell proliferation via an autocrine loop of
PDGF (32). The pretreatment with fibroblast growth factor
(FGF)-2 caused stimulation of PDGF receptor (PDGFR)
alpha expression and ASM cell proliferation was augmented
with IL-4 and IL-13. However, in that study, neither IL-4 nor
IL-13 induced ASM cell proliferation without FGF-2 pre-
treatment, even though they induced PDGF-AA and PDGF-
CC. Since we did not stimulate with FGF-2, the PDGFR
alpha expression might not have been facilitated. However,
we evaluated the ASM cells with and without PDGF-BB,
and IL-4 inhibited cell proliferation in both cases. PDGF-
BB binds to both the PDGFR alpha and PDGFR beta, while
PDGF-AA binds only to the PDGFR alpha (33). PDGFR
beta is five to six times more prominent in the ASM cells
compared to PDGFR alpha and PDGF-BB has a more potent
mitogenic effect than does PDGF-AA (34). Therefore, it is
unlikely that upregulated PDGFR alpha expression was related
to the IL-4-mediated cell proliferation. Further studies are
needed to identify the signaling pathways that mediate IL-
4-induced inhibition of PDGF-enhanced ASM proliferation.
Increased vascularity and enlarged congested mucosal blood
vessels have been reported in biopsy specimens from the air-
ways of asthmatics (35). VEGF is important to angiogenic
activity in the airways. Expression of VEGF and its recep-
tors is upregulated in asthma. The degree of airway vascu-
larity has been found to correlate with VEGF expression (36).
In this study, VEGF release by ASM cells was augmented
by stimulation with IL-4, but not with amphiregulin. Even
though smooth muscle hyperplasia and increased vasculari-
ty are common findings in the airways of asthmatic subjects,
only PDGF enhanced both VEGF release and cell prolifera-
tion. IL-4 increased VEGF release, but it suppressed smooth
muscle proliferation. By contrast, amphiregulin increased
smooth muscle hyperplasia, but did not augment VEGF
release. Even though airway remodeling is associated with
the injury and repair process during allergic inflammation,
factors associated with the remodeling may be different from
those related to the allergic inflammation.
Amphiregulin, a member of the EGF family, plays an im-
portant role in the proliferation of vascular smooth muscle
cells (37), neural stem cells (38), cell survival (39), and differ-
entiation (38). There are only a few reports on the relation-
ship between amphiregulin and airway remodeling in asth-
ma. In a study on asthmatic subjects, amphiregulin expres-
sion was upregulated in the mast cells, in patients with asth-
ma, compared to normal controls. In addition, its upregula-
tion is significantly correlated with the goblet cell hyper-
plasia in the mucosa of the patients with asthma (40). Fur-
thermore, the amphiregulin, secreted from mast cells, pro-
moted the proliferation of primary human lung fibroblasts
and induced lung fibrosis (41). In this study, amphiregulin
augmented human ASM cell proliferation. This is the first
report to demonstrate that amphiregulin promotes ASM cell
proliferation. However, it did not influence the secretion of
VEGF and MCP-1 from human ASM cells. In a chronic asth-
ma mouse model, amphiregulin was not associated with
remodeling of the walls of airways (42). 
In this study, VEGF release from the human ASM cells
was augmented by PDGF stimulation compared to the spon-
taneous release from cells. Since PDGF acted as a strong
growth-stimulant factor in the ASM cells, we investigated
whether VEGF activity was an autocrine growth-stimulant
factor in the ASM cells response to PDGF. We blocked the
VEGF receptor with VEGF R2 antibody and neutralized
VEGF with anti-human VEGF antibody; then the ASM cells
were stimulated with PDGF. VEGF R1, flt-1, VEGF R2,
and KDR were shown to be highly expressed in the ASM
cells (43). However, the blocking and neutralizing antibod-
ies did not inhibit PDGF-enhanced cell proliferation. Fur-
thermore, ASM cells did not proliferate with VEGF stimu-
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finding is consistent with those reported by Kazi et al. (43).
Given the unresponsiveness of the ASM cells to VEGF, VEGF-
receptor blocking and VEGF-neutralizing antibodies, it is
unlikely that VEGF contributes to the smooth muscle hyper-
plasia in airway remodeling. 
MCP-1 and MIP-1αare C-C chemokines; they play an
important role in allergic inflammation, bronchial hyperre-
sponsiveness and the recruitment of eosinophils in bronchial
asthma (44). C-C chemokine receptors for MIP-1αand MCP-
1 were reported to be expressed in vascular smooth muscle
cells (45). In this study, only MCP-1, but not MIP-1α , was
released from ASM cells spontaneously and after IL-4 and
amphiregulin treatment. However, in contrast to VEGF
release, there was no significant difference between the spon-
taneous release and the release associated with IL-4 and am-
phiregulin. 
Our findings suggest that IL-4 may have a bifunctional
role in airway remodeling; one characterized by suppression
of the airway smooth muscle hyperplasia, and the other by
the increase in VEGF release from the airway smooth muscle
cells. Since this was an in vitro cell culture study, the results
include the following limitations. The effects of chronic expo-
sure to IL-4 on airway smooth muscle cell proliferation could
not be evaluated. During the acute phase of bronchial asth-
ma, increased vascular permeability by VEGF leads to mucos-
al edema and airway narrowing. Sustained allergic inflam-
mation over time leads to more permanent structural changes
in the airways including subepithelial fibrosis and smooth
muscle cell hyperplasia. Therefore, IL-4 stimulation for 24
to 48 hr cannot show the chronic effects on smooth muscle
cell proliferation. Nevertheless, IL-4 might be used in the
future as a therapeutic modality for the modification of ASM
cellular proliferation in airway remodeling. Human ASM
cells can also participate in the pathogenesis of asthma by
release of chemokines and growth factors such as MCP-1 and
VEGF, and amphiregulin can promote human ASM cell pro-
liferation. These results suggest potential targets for the devel-
opment of additional asthma therapy.
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